These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 9496913

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
    Kubicka S, Trautwein C, Niehof M, Manns M.
    Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. SV40 T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors.
    Tzeng YJ, Zimmermann C, Guhl E, Berg B, Avantaggiati ML, Graessmann A.
    Oncogene; 1998 Apr 23; 16(16):2103-14. PubMed ID: 9572491
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
    Malkin D, Chilton-MacNeill S, Meister LA, Sexsmith E, Diller L, Garcea RL.
    Oncogene; 2001 Jul 27; 20(33):4441-9. PubMed ID: 11494139
    [Abstract] [Full Text] [Related]

  • 9. Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen.
    Catalano A, Romano M, Martinotti S, Procopio A.
    Oncogene; 2002 Apr 25; 21(18):2896-900. PubMed ID: 11973650
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
    Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL, Koeffler HP.
    Oncogene; 1994 Jul 25; 9(7):1899-906. PubMed ID: 8208536
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. p53 mutants with changes in conserved region II: three classes with differing antibody reactivity, SV40 T antigen binding and ability to inhibit transformation of rat cells.
    Schmieg FI, Simmons DT.
    Oncogene; 1993 Aug 25; 8(8):2043-50. PubMed ID: 8393158
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. An unexpected role for p53 in augmenting SV40 large T antigen-mediated tumorigenesis.
    Herzig M, Novatchkova M, Christofori G.
    Biol Chem; 1999 Feb 25; 380(2):203-11. PubMed ID: 10195427
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.